http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
소아 및 청소년기에 발생하는 악성 난소종양에 관한 임상적 연구
박지원(JW Park),이재관(JK Lee),이용호(YH Lee),이낙우(NW Lee),김영태(YT Kim),서호석(HS Suh),이규완(KW Lee) 대한산부인과학회 1999 Obstetrics & Gynecology Science Vol.42 No.4
Objective: We retrospectively evaluated the frequency, clinical presentation and histopathologic findings of ovarian malignancy in childhood and adolescence. The aim was to analyze the age-specific presentation, type and distribution of adnexal mass, and corresponding patient outcome in surgically evaluated children and adolescents. Methods: The medical records of all patients aged 20 years or less with adnexal mass seen at the Korea University Medical Center from 1988 through 1997 were reviewed. Only those individuals whose diagnosis was established by laparotomy were included. Results: In females 20 years of age and under, borderline or malignant ovarian neoplasms were identified in 14[14.4%] of 97 individuals with adnexal mass and in 14[17.7%] of 79 females with ovarian neoplasms. The frequency of ovarian malignancies correlated inversely with patient age. In the 11-15 age group, 28.6%[six of 21] had malignancies, as compared with 14.5%[eight of 55] in the 16-20 age group and 0% in the 0-10 age group. Germ cell, epithelial, and sex cord-stromal malignancies accounted for 64.3%, 21.4% and 14.3%, respectively, of the 14 cases. Conclusion: The frequency with which ovarian neoplasms represents malignancy in this age group is 17.7%. Because of the potential for malignant ovarian neoplasms in young females, the presence of an abdominal-pelvic mass requires prompt and thorough attention.
( Miseon Kim ),( Young-han Kim ),( Yong Beom Kim ),( Jayeon Kim ),( Jae-weon Kim ),( Mi Hye Park ),( Joo Hyun Park ),( Jeong Ho Rhee ),( Myong Cheol Lim ),( Joon-seok Hong ) 대한산부인과학회 2018 Obstetrics & Gynecology Science Vol.61 No.5
Based on the current understanding of a preventive effect of bilateral salpingectomy on ovarian/fallopian/peritoneal cancers, the Korean Society of Obstetrics and Gynecology, Korean Society of Gynecologic Endocrinology, Korean Society of Gynecologic Oncology, Korean Society of Maternal Fetal Medicine, and Korean Society for Reproductive Medicine support the following recommendations: · Women scheduled for hysterectomy for benign gynecologic disease should be informed that bilateral salpingectomy reduces the risk of ovarian/fallopian/peritoneal cancer, and they should be counseled regarding this procedure at the time of hysterectomy. · Although salpingectomy is generally considered as a safe procedure in terms of preserving ovarian reserve, there is a lack of evidences representing its long-term outcomes. Therefore, patients should be informed about the minimal potential of this procedure for decreasing ovarian reserve. · Prophylactic salpingectomy during vaginal hysterectomy is favorable in terms of prevention of ovarian/fallopian/ peritoneal cancer, although operation-related complications minimally increase with this procedure, compared to the complications associated with vaginal hysterectomy alone. Conversion to open or laparoscopic approach from vaginal approach to perform prophylactic salpingectomy is not recommended. · Women who desire permanent sterilization at the time of cesarean delivery could be counseled for prophylactic salpingectomy before surgery on an individual basis.
원격전이된 재발성 난소 윤상소관형 성기삭 종양 ( SCTAT ) 의 화학요법 경험 1 예
김관식(KS Kim),오병찬(BC Oh),진소자(SJ Jin),김종덕(JD Kim) 대한산부인과학회 1998 Obstetrics & Gynecology Science Vol.41 No.6
Sex cord tumor with annular tubules (SCTAT) is an unusual ovarian neoplasm. The standard treatment for recurrent SCTAT was not established. This tumor was considered as a tumor with low-grade malignancy. A case of recurrent ovarian sex cord tumor with annular tubules in a 24-year old female with Turner`s syndrome was reported. The recurrence and metastasis were diagnosed accidentally through the operation of a palpable neck mass in the department of ENT in our hospital. Retroperitoneal lymphatic metastasis was thought to an important pathway of spread. Persistent amenorrhea, pelvic mass, and para-aortic masses were important clinical features. The patient was treated with combination chemotherapy of three cycles. The regimen consisted of bleomycin, etoposide, and cisplatin.
난소-자궁부속기 종괴: 다중기법 MR 영상의 임상 적용과 O-RADS MRI
Eom So Young,Rha Sung Eun 대한영상의학회 2021 대한영상의학회지 Vol.82 No.5
초음파에서 우연히 접하는 자궁부속기 병변은 양성 병변이 더 흔하지만, 일부는 악성도가 애매한 병변으로 간주되어 추가적인 평가를 위해 다중매개변수 MRI가 필요하다. 고식적 MRI 를 통해 해부학적 모양을 살피고, 지방, 출혈, 섬유성 조직, 고형성 조직 등 병변의 구성성분을 파악하여 많은 양성 종괴들을 정확하게 진단할 수 있다. 또한 추가적인 확산강조영상과역동적 조영증강 기법의 관류영상으로 양성과 악성의 감별 진단 정확도를 높일 수 있다. 최근 자궁부속기 종괴의 악성 위험도를 평가하고, 각 위험도 군에 대한 적절한 조치를 권고하는데 있어 표준화된 의사소통이 가능하도록 하기 위해 난소-자궁부속기 MRI 보고 및 자료시스템(ovarian-adnexal reporting and data system MRI; 이하 O-RADS MRI)이 발표되었다. 본 종설에서는 자궁부속기 종괴의 악성도 예측 및 감별 진단을 위한 다중매개변수 MRI 의 임상 적용과 O-RADS MRI에 대하여 기술하고자 한다. Incidental adnexal masses considered indeterminate for malignancy are commonly observed on ultrasonography. Multiparametric MRI is the imaging modality of choice for the evaluation of sonographically indeterminate adnexal masses. Conventional MRI enables a confident pathologic diagnosis of various benign lesions due to accurate tissue characterization of fat, blood, fibrous tissue, and solid components. Additionally, functional imaging sequences, including perfusion- and diffusion-weighted imaging, improve the diagnostic efficacy of conventional MRI in differentiating benign from malignant adnexal masses. The ovarian-adnexal reporting and data system (O-RADS) MRI was recently designed to provide consistent interpretations in assigning risk of malignancy to ovarian and other adnexal masses, and to provide a management recommendation for each risk category. In this review, we describe the clinical application of multiparametric MRI for the evaluation of adnexal masses and introduce the O-RADS MRI risk stratification system.
Pedunculated mucinous cystic neoplasm of the liver: a case report
Sang-Woo Ha,Shin Hwang,Hyejin Han,Song Ie Han,Seung Mo Hong 영남대학교 의과대학 2022 Yeungnam University Journal of Medicine Vol.39 No.3
In 2010, the World Health Organization classified mucin-producing bile duct tumors of the liver into two distinct entities; mucinous cystic neoplasm of the liver (MCN-L) and intraductal papillary mucinous neoplasm of the bile duct. We present the case of a patient with MCN-L having a uniquely pedunculated shape. A 32‐year‐old woman was referred to our institution with a diagnosis of biliary cystic neoplasm. She had undergone left salpingo-oophorectomy for ovarian cancer 15 years ago. Imaging studies showed an 8 cm-sized well defined, multiloculated cystic lesion suggesting a mucinous cystic neoplasm. The cystic mass was pedunculated at the liver capsule and pathologically diagnosed as MCN-L. The mass was resected with partial hepatectomy. The patient recovered uneventfully. She was discharged 7 days postoperatively. The patient has been doing well for 6 months after the operation. The patient will be followed up annually because of the favorable postresection prognosis of MCN-L.
윤만수 ( Man Soo Yoon ),장성규 ( Sung Kyu Jang ),이동형 ( Dong Hyung Lee ),김기형 ( Ki Hyung Kim ),나용진 ( Yong Jin Na ),김활웅 ( Hwal Woong Kim ),김지연 ( Jee Yeon Kim ),최경운 ( Kyung Un Choi ) 대한산부인과학회 2006 Obstetrics & Gynecology Science Vol.49 No.7
Objective: MTA1 has been identified as a metastasis-promiting gene, and its gene expression is correlated with invasion and metastasis in several cancers. We examined MTA1 expression levels in epithelial ovarian neoplasm. Methods: Expression of MTA1 was evaluated by immunohistochemistry and tissue array in 53 benign tumors, 27 borderline tumors and 68 malignant tumors. The data was analyzed in reference to various clinicopathological parameters. Results: Increased expression of MTA1 was significantly correlated with histologic grade and FIGO stage. There was no relationship between MTA1 expression and age, histologic type, tumor size. Conclusion: These results suggest that MTA1 is closely related to invasiveness and progression in epithelial ovarian neoplasm. The MTA1 could thus potentially provide information on the mechanism of cancer invasion and metastasis.
Urothelial (Transitional Cell) Carcinoma Arising in Mature Cystic Teratoma - A Case Report -
이호창,이옥준 대한병리학회 2010 Journal of Pathology and Translational Medicine Vol.44 No.6
Mature cystic teratoma (MCT) is one of the most common benign ovarian tumors, but 1-2% of MCTs are transformed to a malignant neoplasm. Urothelial carcinoma (UC) or transitional cell carcinoma is the most common cancer in the urinary tract. However, UC is a very rare component of transformed malignancy of MCT. Here we report a case of UC arising in an MCT in a 52-year-old woman. Grossly, the ovary was partly cystic and partly solid. Microscopically, the cyst revealed the classic features of MCT and the solid area was papillary UC. By immunohistochemistry using cytokeratins and thrombomodulin, the UC showed a similar expression to that of UC arising in the urinary tract, rather than resembling a primary transitional cell carcinoma of the ovary. When UC is found in a component of MCT, the origin of the carcinoma should be evaluated and urinary tract examinations are required to rule out metastasis.
AGR2, a mucinous ovarian cancer marker, promotes cell proliferation and migration
Park, Kyoung-Sook,Chung, Yong-Jin,So, Hye-Kyung,Kim, Kwang-Soo,Park, Jun-Soo,Oh, Mi-Joung,Jo, Min-Wha,Choi, Kyu-Sam,Lee, Eun-Ju,Choi, Yoon-La,Song, Sang-Yong,Bae, Duk-Soo,Kim, Byoung-Gie,Lee, Je-Ho Korean Society for Biochemistry and Molecular Bion 2011 Experimental and molecular medicine Vol.43 No.2
Ovarian cancer is a leading cause of death in women. Early detection of ovarian cancer is essential to decrease mortality. However, the early diagnosis of ovarian cancer is difficult due to a lack of clinical symptoms and suitable molecular diagnostic markers. Thus, identification of meaningful tumor biomarkers with potential clinical application is clearly needed. To search for a biomarker for the early detection of ovarian cancer, we identified human anterior gradient 2 (AGR2) from our systematic analysis of paired normal and ovarian tumor tissue cDNA microarray. We noted a marked overexpression of AGR2 mRNA and protein in early stage mucinous ovarian tumors compared to normal ovarian tissues and serous type ovarian tumors by Western blot analysis and immunohistochemistry. To further elucidate the role of AGR2 in ovarian tumorigenesis, stable 2774 human ovarian cancer cell lines overexpressing AGR2 were established. Forced expression of AGR2 in 2774 cells enhanced the growth and migration of ovarian cancer cells. AGR2 protein was detected in the serum of mucinous ovarian cancer patients by Western blot and ELISA analysis. Thus, AGR2 is a potential biomarker for the diagnosis of mucinous ovarian cancer and an ELISA assay may facilitate the early detection of mucinous ovarian cancer using patient serum.
AGR2, a mucinous ovarian cancer marker, promotes cell proliferation and migration
이제호,Kyoungsook Park,Yong Jin Chung,Hyekyung So,김광수,박준수,Mijoung Oh,Minwha Jo,Kyusam Choi,이은주,Yoon-La Choi,Sang Yong Song,배덕수,김병기 생화학분자생물학회 2011 Experimental and molecular medicine Vol.43 No.2
Ovarian cancer is a leading cause of death in women. Early detection of ovarian cancer is essential to decrease mortality. However, the early diagnosis of ovarian cancer is difficult due to a lack of clinical symptoms and suitable molecular diagnostic markers. Thus,identification of meaningful tumor biomarkers with potential clinical application is clearly needed. To search for a biomarker for the early detection of ovarian cancer,we identified human anterior gradient 2 (AGR2)from our systematic analysis of paired normal and ovarian tumor tissue cDNA microarray. We noted a marked overexpression of AGR2 mRNA and protein in early stage mucinous ovarian tumors compared to normal ovarian tissues and serous type ovarian tumors by Western blot analysis and immunohistochemistry. To further elucidate the role of AGR2 in ovarian tumorigenesis,stable 2774 human ovarian cancer cell lines overexpressing AGR2 were established. Forced expression of AGR2 in 2774 cells enhanced the growth and migration of ovarian cancer cells. AGR2 protein was detected in the serum of mucinous ovarian cancer patients by Western blot and ELISA analysis. Thus,AGR2 is a potential biomarker for the diagnosis of mucinous ovarian cancer and an ELISA assay may facilitate the early detection of mucinous ovarian cancer using patient serum.
Ovarian cancer screening in menopausal females with a family history of breast or ovarian cancer
Tiffany Lai,Bruce Kessel,Hyeong Jun Ahn,Keith Y. Terada 대한부인종양학회 2016 Journal of Gynecologic Oncology Vol.27 No.4
Objective: To determine whether annual screening reduces ovarian cancer mortality in women with a family history of breast or ovarian cancer. Methods: Data was obtained from the Prostate, Lung, Colorectal, and Ovarian cancer trial, a randomized multi-center trial conducted to determine if screening could reduce mortality in these cancers. The trial enrolled 78,216 women, randomized into either a screening arm with annual serum cancer antigen 125 and pelvic ultrasounds, or usual care arm. This study identified a subgroup that reported a first degree relative with breast or ovarian cancer. Analysis was performed to compare overall mortality and disease specific mortality in the screening versus usual care arm. In patients diagnosed with ovarian cancer, stage distribution, and survival were analyzed as a secondary endpoint. Results: There was no significant difference in overall mortality or disease specific mortality between the two arms. Ovarian cancer was diagnosed in 48 patients in the screening arm and 44 patients in the usual care arm. Screened patients were more likely to be diagnosed at an earlier stage than usual care patients. Patients in the screening arm diagnosed with ovarian cancer experienced a significantly improved survival compared to patients in the usual care arm; relative risk 0.66 (95% CI, 0.47 to 0.93). Conclusion: Screening did not appear to decrease ovarian cancer mortality in participants with a family history of breast or ovarian cancer. Secondary endpoints, however, showed notable differences. Significantly fewer patients were diagnosed with advanced stage disease in the screening arm; and survival was significantly improved. Further investigation is warranted to assess screening efficacy in women at increased risk.